Biotech

CV Technologies Announces Delay in Filing Annual Financial Statements

Fri, 26 Dec 2008 15:32:00 EST

EDMONTON, ALBERTA--(eMediaWorld - Dec. 26, 2008) - (TSX:CVQ) CV Technologies Inc. (the "Company") announces that it is not able to file its annual financial statements, accompanying management's discussion and analysis, and related CEO and CFO certifications (collectively, the "2008 Annual Financial Statements") for the financial year ended September 30, 2008 within the 90 day period prescribed for the filing of annual financial statements under Parts 4 and 5 of National Instrument 51-102 and pursuant to National Instrument 52-109, respectively. The Company expects to file the Annual Financial Statements on or before January 12, 2009.

AspenBio Expands Board With Addition of John H. Landon

Mon, 22 Dec 2008 09:00:00 EST

CASTLE ROCK, CO--(eMediaWorld - December 22, 2008) - AspenBio Pharma, Inc. (NASDAQ: APPY), an emerging bio-pharmaceutical company dedicated to the development of novel drugs and diagnostics for humans and animals, has appointed John H. Landon as an independent member of its board of directors. This appointment brings the total number of company directors to eight, with six serving independently. Mr. Landon's career includes more than 30 years of broad, multi-functional experience with the DuPont Company. Prior to retiring from active management, Mr. Landon served as vice president and general manager of medical products for DuPont. He had worldwide responsibility for all of DuPont's medical products businesses, encompassing total annual sales of $1 billion and more than 5,000 employees. In addition to other director roles, Mr. Landon served as chairman of the board of Cholestech Corporation prior to its 2007 sale to

GSK and Theravance Announce Positive Phase 2b Results for LABA '444 in the Treatment of COPD in the Horizon Development Programme

Mon, 22 Dec 2008 08:00:00 EST

LONDON and SOUTH SAN FRANCISCO, CA--(eMediaWorld - December 22, 2008) - GlaxoSmithKline Plc (GSK) and Theravance, Inc. (NASDAQ: THRX) today announced positive results from the Phase 2b study of the novel, long-acting beta agonist (LABA) GW642444 ('444) in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD). The study evaluated the dose response, efficacy and safety of five doses of '444 administered once-daily for four weeks. All doses achieved statistically significant increases in lung function (trough FEV1) compared to placebo (p < 0.05). The changes were dose-dependent with the two highest doses (25 and 50 mcg) exceeding a predefined threshold of 130 mL increase in FEV1 at trough.

Prostrakan and Paladin Complete Agreement for Abstral(R) and Sancuso(R)

Mon, 22 Dec 2008 07:00:00 EST

MONTREAL, QUEBEC--(eMediaWorld - Dec. 22, 2008) - Paladin Labs Inc. (TSX:PLB), a leading Canadian specialty pharmaceutical company, today announced that it has entered into a licensing and distribution agreement under which ProStrakan Group plc (LSE:PSK) has granted Paladin the exclusive Canadian rights to market and sell Abstral(R) (sublingual fentanyl) and Sancuso(R) (granisetron transdermal patch). Financial terms of the deal were not disclosed. Abstral(R) is a rapid dissolving, sub-lingual tablet of fentanyl, indicated for the management of breakthrough cancer pain in patients who are already receiving opioid analgesics. Abstral(R) is currently approved in Sweden, Denmark, United Kingdom and Germany. There is currently no immediate release fentanyl available for sale in Canada. In the United States, immediate release fentanyl recorded more than US $500 million in sales in 2007.

Accord intervenu entre Prostrakan et Paladin relativement à Abstral(R) et à Sancuso(R)

Mon, 22 Dec 2008 07:00:00 EST

MONTREAL, QUEBEC--(eMediaWorld - 22 déc. 2008) - Laboratoires Paladin Inc. (TSX:PLB), une entreprise pharmaceutique canadienne spécialisée de premier rang, a annoncé aujourd'hui la conclusion d'un accord de licence et de distribution en vertu duquel ProStrakan Group plc (LSE:PSK) octroie à Paladin les droits exclusifs au Canada de procéder à la commercialisation et à la vente de Abstral(R) (comprimés de fentanyl administrés par voie sublinguale) et de Sancuso(R) (timbres de granisétron transdermiques). Les dispositions financières de l'accord n'ont pas été divulguées.

Myriad Genetics Launches Sixth Personalized Medicine Product, Prezeon -- to Reveal PTEN Status

Mon, 22 Dec 2008 06:30:00 EST

PTEN Gene Associated With Cancer Prognosis and Choice of Chemotherapy

SciClone Announces First Patient Enrolled in Phase 2 Clinical Trial Using SCV-07 to Prevent Oral Mucositis

Mon, 22 Dec 2008 06:30:00 EST

FOSTER CITY, CA--(eMediaWorld - December 22, 2008) - SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced the enrollment of its first patient in its phase 2, multi-center, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of SCV-07 for prevention of oral mucositis (OM) in patients receiving radio-chemotherapy for the treatment of head and neck cancer. "Despite its frequency, pain, adverse impact on health, and healthcare cost, there are very few treatment options available for oral mucositis," said Stephen T. Sonis, DMD, DMSc, Brigham and Women's Hospital, Boston, MA. "Data from the preclinical studies of SCV-07 were very promising, showing a compelling prevention of oral mucositis. Intriguingly, the preclinical models also showed a decrease in tumor growth in addition to preventing oral mucositis. And, SCV-07 was well-tolerated. Based on these significant findings, we be

OctoPlus Wins New Technology Evaluation Contract

Mon, 22 Dec 2008 02:16:00 EST

LEIDEN, NETHERLANDS--(eMediaWorld - December 22, 2008) - As part of the Company's recently announced strategic focus on using its controlled release technology for clients, OctoPlus N.V. ("OctoPlus" or "the Company") (Euronext: OCTO) announces today that it has signed a new technology evaluation contract with a large UK-based company. OctoPlus' strategy will increasingly focus on developing controlled release versions of existing or new drugs for clients, in addition to providing general formulation development and clinical material manufacturing. Currently, OctoPlus is working on six projects utilising its controlled release technology for a client.

Mission Regional Medical Center Selects IntelliDOT as a Key Component of Its Bedside Patient Safety Initiative

Thu, 18 Dec 2008 11:38:00 EST

IntelliDOT Phlebotomy Specimen Collection(TM) to Be Installed Q1 2009

Ambrilia entreprend de nouvelles mesures de compression des coûts et explore d'autres solutions stratégiques pour accroître la valeur pour les actionnaires

Thu, 18 Dec 2008 11:00:00 EST

Attention directeurs des rubriques affaires/finance/santé

Ambrilia Takes Additonal Cost-Cutting Actions and Explores Alternative Strategic Options to Enhance Shareholder Value

Thu, 18 Dec 2008 11:00:00 EST

Attention Business/Financial/Health Editors

GLG Life Tech Corporation Announces Cargill Receives FDA Clearance for Use of Rebiana

Thu, 18 Dec 2008 06:30:00 EST

VANCOUVER, BRITISH COLUMBIA--(eMediaWorld - Dec. 18, 2008) - GLG Life Tech Corporation (TSX:GLG) ("GLG" or the "Company") announces today that the Food and Drug Administration of the United States ("FDA") confirmed that it had no objection to the conclusion of an independent expert panel which reviewed research on rebiana and concluded that it is generally recognized as safe (GRAS) for use as a general purpose sweetener, including for use in food and beverages. Rebiana is an all natural, zero calorie sweetener made with 97% Rebaudioside A from the leaves of the stevia plant.

AspenBio Receives Patent Office Notice of Allowance for Appendicitis Diagnostic Methods

Wed, 17 Dec 2008 09:00:00 EST

CASTLE ROCK, CO--(eMediaWorld - December 17, 2008) - AspenBio Pharma, Inc. (NASDAQ: APPY), an emerging bio-pharmaceutical company dedicated to the development of novel drugs and diagnostics for humans and animals, announced the United States Patent and Trademark Office has issued a Notice of Allowance for AspenBio's United States patent application directed to methods relating to its appendicitis diagnostic technology. The patent application is U.S. Application Serial No. 11/189,120, entitled 'Methods and Devices for Diagnosis of Appendicitis' (first published as U.S. Patent Application Publication Number 20060024719 on February 2, 2006). The newly allowed claims include subject matter covering aspects of blood-based appendicitis testing.

Theratechnologies Closes its Collaboration and Licensing Transaction With EMD Serono

Tue, 16 Dec 2008 08:45:00 EST

Theratechnologies receives an upfront payment of US$30 million (CDN$37.0 million)

Theratechnologies procède à la clôture de la transaction portant sur l'entente de collaboration et de licence avec EMD Serono

Tue, 16 Dec 2008 08:45:00 EST

Theratechnologies reçoit un paiement initial de 30 M$ US (37,0 M$ CAN)

KIKA CEO Linda Beneze Urges EDC Vendors to Ensure Sponsors 24x7 Access to Clinical Data

Mon, 15 Dec 2008 09:00:00 EST

Cites Critical Importance of Data Replication to Avoid Costly Patient Re-Enrollment in Clinical Trials

Adeona Pharmaceuticals Expands Patent Estate for Oral TRIMESTA Through an Option Agreement With University of Kansas

Mon, 15 Dec 2008 08:44:00 EST

Complements Existing Intellectual Property Portfolio for Oral TRIMESTA

APOSENSE(R) Apoptosis Imaging Program for Cancer Therapy Monitoring Initiates a Phase II Multi-Center Study at Memorial Sloan-Kettering Cancer Center

Mon, 15 Dec 2008 08:30:00 EST

Study Will Be Performed Under Recently Opened IND to Evaluate Safety and Efficacy of [18F]-ML-10 in Early Detection of Response of Metastatic Brain Tumors to Radiotherapy

Laboratoires Paladin annonce l'instauration d'un régime d'achat automatique d'actions

Mon, 15 Dec 2008 08:00:00 EST

MONTREAL, QUEBEC--(eMediaWorld - 15 déc. 2008) - Laboratoires Paladin Inc. (TSX:PLB) ("Paladin" ou la "société"), chef de file de l'industrie pharmaceutique spécialisée au Canada, a annoncé aujourd'hui qu'elle avait instauré avec un courtier un régime d'achat automatique d'actions afin de faciliter le rachat de ses actions ordinaires dans le cadre de son offre publique de rachat dans le cours normal des activités. Paladin a précédemment annoncé qu'elle avait obtenu l'approbation de la Bourse de Toronto (la "TSX") pour lancer une offre publique de rachat dans le cours normal des activités devant lui permettre de racheter jusqu'à concurrence de 786 000 actions ordinaires, ce qui représente environ 10 % de son flottant qui, au 15 février 2008, comptait 7 867 694 actions ordinaires. L'offre publique de rachat dans le cours normal des activités a débuté le 3 mars 2008 et prendra fin le 2 mars 2009, ou plus tôt, selon le nombre d'actions que Paladin aura rachetées dans le cadre de l'offre.

Paladin Labs Announces Automatic Share Purchase Plan

Mon, 15 Dec 2008 08:00:00 EST

MONTREAL, QUEBEC--(eMediaWorld - Dec. 15, 2008) - Paladin Labs Inc. (TSX:PLB), a leading Canadian specialty pharmaceutical company, today announced that it has entered into an automatic share purchase plan with a broker in order to facilitate repurchases of its common shares under its normal course issuer bid. Paladin previously announced that it had received approval from the Toronto Stock Exchange ("TSX") to make a normal course issuer bid to purchase up to 786,000 common shares, being approximately 10% of its public float of 7,867,694 common shares as at February 15, 2008. The normal course issuer bid commenced on March 3, 2008 and will terminate on March 2, 2009, or such earlier date as Paladin may complete repurchases under the bid.

Symyx Assay Explorer(R) Software Improves Biology Data Capture and Collaboration

Mon, 15 Dec 2008 08:00:00 EST

Enhanced Data Searching and Display Increase Value of In Vivo and In Vitro Data

Conférence téléphonique et avis aux médias : Theratechnologies annonce les résultats de son étude confirmatoire de phase 3 après 52 semaines de traitement

Sun, 14 Dec 2008 18:48:00 EST

MONTREAL, QUEBEC--(eMediaWorld - 14 déc. 2008) - Theratechnologies (TSX:TH) souhaite annoncer la tenue d'une conférence téléphonique et d'une webdiffusion afin de discuter des résultats de son étude confirmatoire de phase 3, après 52 semaines de traitement avec la tésamoréline, chez des patients atteints de la lipodystrophie associée au VIH. La conférence sera dirigée par Mme Andrea Gilpin, vice-présidente, relations avec les investisseurs et communications, chez Theratechnologies. M. Yves Rosconi, président et chef de la direction, M. Luc Tanguay, premier vice-président exécutif et chef de la direction financière, Dr Pierre Caudrelier, chef de la direction médicale, et M. Christian Maroslais, vice-président, recherche clinique, participeront également à la conférence.

Notice of Conference Call & Media Advisory: Theratechnologies reports 52-week confirmatory Phase 3 results

Sun, 14 Dec 2008 18:47:00 EST

MONTREAL, QUEBEC--(eMediaWorld - Dec. 14, 2008) - Theratechnologies (TSX:TH) advises of an upcoming conference call and webcast to discuss the 52-week results of its confirmatory Phase 3 clinical trial, testing tesamorelin, in patients with HIV-associated lipodystrophy. The call will be moderated by Dr. Andrea Gilpin, Vice President, IR & Communications, at Theratechnologies. Mr. Yves Rosconi, President and CEO, Mr. Luc Tanguay, Senior Executive Vice President and CFO, Dr. Pierre Caudrelier, Chief Medical Officer and Dr. Christian Marsolais, Vice President, Clinical Research, will also be participating.

Shortfall in Human Blood Supply Spurs Innovation in Synthetic Substitutes

Fri, 12 Dec 2008 08:40:00 EST

NEW YORK, NY--(eMediaWorld - December 12, 2008) - The market for human blood and blood components continues to expand in correlation with the world's growing and aging populations, particularly in the United States, Japan, and Europe. According to a new report from Kalorama Information entitled "Blood: The Worldwide Market for Blood Products, Blood Testing, Blood Equipment, and Synthetic Blood Products," a shortfall in human blood supply is prompting the development of synthetic blood products.

Functional Technologies Receives PEI Business Development Grant

Fri, 12 Dec 2008 08:30:00 EST

Completes Acquisition of State-Of-The-Art Drying Technology Company

SGLT2 Inhibitors a Promising New Therapy for Type II Diabetes: New Cutting Edge Information Report Analyzes Diabetes Market Forecast Through 2013

Fri, 12 Dec 2008 08:12:00 EST

RESEARCH TRIANGLE PARK, NC--(eMediaWorld - December 12, 2008) - A new drug class is poised to make a splash in the diabetes market, according to a new report, "Diabetes Market Forecast to 2013" (http://www.cuttingedgeinfo.com/Diabetes/ index.htm#body), published by Cutting Edge Information. SGLT2 Inhibitors, which block the reabsorption of glucose in the kidneys, have had positive clinical results and have attracted the attention of top pharmaceutical companies. While no SGLT2 inhibitor is currently FDA-approved, this class is expected to generate more than $500 million in revenue by 2011.

Cytokinetics Announces Clinical and Preclinical Data Regarding Ispinesib Presented at the 31st Annual San Antonio Breast Cancer Symposium

Fri, 12 Dec 2008 08:00:00 EST

SOUTH SAN FRANCISCO, CA--(eMediaWorld - December 12, 2008) - Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that two posters, one summarizing interim Phase I clinical trial data evaluating ispinesib in the treatment of breast cancer and another containing preclinical data for ispinesib, were presented at the 31st Annual San Antonio Breast Cancer Symposium (SABCS) held on December 10-14, 2008. Ispinesib is a novel, small molecule inhibitor of kinesin spindle protein (KSP), a mitotic kinesin essential for proper cell division, being developed by Cytokinetics under a collaboration with GlaxoSmithKline.

OR-Live Presents: 20 Years Later . . . The Evolution of Lap Chole

Fri, 12 Dec 2008 05:46:00 EST

Twenty Years of Minimally Invasive Gallbladder Surgery and Future Trends; January 8, 2009 at 7PM EST From Drexel University College of Medicine

OR-Live Presents: Webcast Featuring Laparoscopic Roux-en-Y Gastric Bypass Surgery

Thu, 11 Dec 2008 15:13:00 EST

From the Bariatric Center at Saint Francis Hospital: January 7, 2009 at 9:00 AM EST

KIKA Medical Celebrates 3rd Year of Preferred Provider Status of Next-Generation EDC for Clinical Asset Management to Global CRO Cardialysis

Thu, 11 Dec 2008 14:55:00 EST

Independent CRO Focusing on Cardiovascular Indication for Pharmaceutical and Device Markets Cites KIKA Expertise, Speed and Flexibility

Perceptronix to Exhibit at Vancouver District and Dental Society Annual MidWinter Clinic

Thu, 11 Dec 2008 12:25:00 EST

VANCOUVER, BRITISH COLUMBIA--(eMediaWorld - Dec. 11, 2008) - Perceptronix will be exhibiting at the Vancouver and District Dental Society Annual MidWinter Clinic on December 12, 2008 at the Westin Bayshore Resort & Marina in Vancouver. Perceptronix will be showcasing OralAdvance(TM), a new quantitative cytology test for the early detection of oral cancer, and demonstrating its use at booth 58. With recent advances in visualization techniques for the oral cavity, dentists are encountering more suspicious lesions. OralAdvance(TM), with its soft cyto-brush sample collection kit, provides dentists with an informative new option for assessing these lesions when biopsy is not warranted or possible. It provides an objective measure of gross DNA abnormality that can give additional information about the pre-malignant or malignant nature of a lesion.

IBC Life Sciences Announces Biopharmaceutical Development & Production Week March 2-6, 2009 in Carlsbad, California

Thu, 11 Dec 2008 12:15:00 EST

WESTBOROUGH, MA--(eMediaWorld - December 11, 2008) - IBC is pleased to announce Biopharmaceutical Development & Production Week which includes five conferences focused on these specific biopharmaceutical disciplines: antibody development and production, outsourcing manufacturing, process validation, technology transfer and non-antibody protein therapeutics. This week long event provides biopharmaceutical professionals the opportunity to network face-to-face with 700 industry peers and is comprised of over 120 presentations that include exclusive case studies, interactive workshop sessions, industry panels, and strategic discussion groups.

Cancer Detection Corporation Provides Corporate Update

Thu, 11 Dec 2008 08:00:00 EST

CONIFER, CO--(eMediaWorld - December 11, 2008) - Cancer Detection Corporation, formerly Xpention Genetics, Inc. (OTCBB: CCDC), provided a corporate update in a letter to shareholders released today, excerpts of which are contained below: "This has been an eventful year for the Company, and I would like to take this opportunity to update our shareholders on our progress to date as well as our future plans. In early 2007, research scientists at the University of Texas Health Science Center at San Antonio obtained promising results in their research to create a canine cancer detection test. These results could not immediately be validated by a third party and we were unable to isolate a particular reason for the inability to validate the results. Nevertheless, due to the potential promise of the p65 technology management perceived, we created a plan to raise new capital and continue research activities.

Merck Continues Nearly $1 Billion in Projects and Outlines Long-Term Strategy, an Industrial Info News Alert

Thu, 11 Dec 2008 06:00:00 EST

SUGAR LAND, TX--(eMediaWorld - December 11, 2008) - Researched by Industrial Info Resources (Sugar Land, Texas) -- On top of its efforts to become a leaner firm, Merck & Company Incorporated (NYSE:MRK) (Whitehouse Station, New Jersey) plans to accelerate the development of a more customer-centric business model as it transitions into a newer Merck. "Next year will continue to be a period of fundamental transformation that establishes Merck as a different competitor in the next decade," Richard Clark, Chairman, President and CEO, said at the company's annual business briefing. "This new Merck will be built for the new era that our industry has entered, and it will be built for long-term success." Industrial Info is tracking eight active projects worth $967 million involving Merck as part of our Pharmaceutical Tracker - Online Database. The projects include

Skyepharma PLC - Research Update

Thu, 11 Dec 2008 05:00:00 EST

London, UK--(eMediaWorld - December 11, 2008) - SkyePharma Announces Successful Completion of Phase I Study for Sleep Maintenance Product (SKP-1041) LONDON, UK, 11 December 2008 -- SkyePharma PLC (LSE: SKP) and its partner, Somnus Therapeutics, Inc., today announce the successful completion of the first Phase I trial of their controlled release sleep maintenance product, SKP-1041. Under the terms of the agreement between SkyePharma and Somnus, a USUSD1 million milestone payment is now payable to SkyePharma. SKP-1041 is a new formulation of zaleplon, a non-benzodiazepine hypnotic agent, which utilises SkyePharma's proprietary GeoclockTM technology for controlled release. The formulation is designed to treat people who have difficulty maintaining sleep but not sleep onset, and is intended to prevent middle-of-the-night awakening while avoiding daytime drowsiness. In June 2007, SkyePharma entered into an exclusiv

Petroleum Communication Holdings Finalizes Purchase in Stem Cell Company

Wed, 10 Dec 2008 12:42:00 EST

LARGO, FL--(eMediaWorld - December 10, 2008) - Petroleum Communication Holdings, Inc. (PTLC) Formerly "AIT Wireless, Inc." (PINKSHEETS: PTLC), announced last week it had entered into an agreement to acquire a 15% equity position in AmeReGen-ImmunoCure Corp. The company has now finalized the purchase. Privately held AmeReGen-ImmunoCure has the technology and global exclusive manufacturing rights for the highest quality assured mass-production of CITA T-cell therapeutics for many of the hardest-to-treat cancers.

Symbollon Enters Into Sale/License Agreement Covering Upper Respiratory Tract Technology

Wed, 10 Dec 2008 11:53:00 EST

FRAMINGHAM, MA--(eMediaWorld - December 10, 2008) - Symbollon Pharmaceuticals, Inc. (OTCBB: SYMBA) announced that on December 8, 2008 it signed a sale/license agreement with BioCide Pharma, Inc. covering upper respiratory tract products based on Symbollon's proprietary iodine-based technology. Under the agreement, Symbollon will transfer ownership of its patent application covering use of its technology in the upper respiratory tract. As partial consideration under the agreement, Symbollon will receive an equity position in BioCide equal to 50% ownership of the company.

AspenBio Completes Clinical Study Patient Enrollment for AppyScore, World's First Blood-Based Diagnostic Test for Human Appendicitis

Wed, 10 Dec 2008 11:34:00 EST

Enrollment Target of 800 Patients Achieved for FDA 510(k) Clinical Trial

ONI BioPharma Announces Its Listing on Alternext Paris

Wed, 10 Dec 2008 09:24:00 EST

ONI BioPharma Will Be the First US Company to List on Alternext Paris

China Aoxing Pharmaceutical Company Obtains a New Production License for Pain Medicine

Wed, 10 Dec 2008 09:00:00 EST

NEW YORK, NY--(eMediaWorld - December 10, 2008) - China Aoxing Pharmaceutical Company, Inc. (OTCBB: CAXG) ("China Aoxing"), a China-based pharmaceutical company specializing in research, development, manufacturing and distribution of narcotic and pain-management products, today announced that its operating subsidiary in China, Hebei Aoxing Pharmaceutical Group Company, Ltd., received a new production license from the China State Food and Drug Administration ("SFDA") for Paracetamol and Caffeine Tablets, a controlled substance regulated by the SFDA.

CLSI Publishes Guideline for Cervicovaginal Cytology Based on the Papanicolaou Technique

Tue, 09 Dec 2008 09:40:00 EST

WAYNE, PA--(eMediaWorld - December 9, 2008) - To help health care professionals provide quality testing, Clinical and Laboratory Standards Institute (CLSI) updated the document "Cervicovaginal Cytology Based on the Papanicolaou Technique; Approved Guideline--Third Edition" (GP15-A3). Routine cervical screening is recognized as the most effective method of reducing the incidence and mortality of cervical cancer. The test has become a means for the medical profession to regularly review the cervical health status of women. GP15-A3 includes updated recommendations for cervicovaginal specimen collection, as well as the preparation, fixation, staining, and storage of Papanicolaou-stained cervicovaginal cytology slides. By following the recommendations of this new updated guideline, laboratory professionals and cytopathology clinicians will highly increase the quality of specimen processing resulting in a more accurate cytologic test.

CardioComm Solutions, Inc. Announces Changes to Board of Directors

Tue, 09 Dec 2008 09:00:00 EST

VICTORIA, BRITISH COLUMBIA--(eMediaWorld - Dec. 9, 2008) - CardioComm Solutions, Inc. (TSX VENTURE:EKG) ("CardioComm" or the "Company") is pleased to announce that Michael Paquin and Yury Levin have been appointed to the board of directors, effective immediately. Michael Paquin is well recognized as a leading healthcare strategist. His insight and innovation to device connectivity into the EMR have been acknowledged by Microsoft, Frost & Sullivan, TEPR and TETHIC. Previously as the President of Midmark Diagnostic Group (Brentwood), Mr. Paquin was the first to develop an innovative strategy for integrating medical devices into over 70 EMRs. With 30+ years experience in working with physicians, he brings a unique perspective addressing the needs of the back office as they relate to the paperless office. He was the past Chair MSHUG 2005-2006 (Microsoft Healthcare Users Group) and as V.P. of one of the nation's largest healthcare information organizations, Mr. Paquin utilizes this unique in

Cavit Sciences Is Now in the Hands of the Shareholders and Moving Forward

Tue, 09 Dec 2008 09:00:00 EST

PATERSON, NJ--(eMediaWorld - December 9, 2008) - Cavit Sciences, Inc. ("Cavit") (OTCBB: CVIT) announced today the following update to its shareholders: To: The Shareholders of Cavit Sciences, Inc. From: Margaret ("Maggie") Smyth, Interim CEO "Cavit Sciences is now in the hands of the shareholders." This means: Management is made up of shareholders with nothing to gain, like all shareholders, until we are an income producing company, which means we are all in the same boat.

With the Pharmaceutical Industry Relying on M&A in 2009, Cutting Edge Information Provides Insight to Avoid Potential Pitfalls

Tue, 09 Dec 2008 08:17:00 EST

RESEARCH TRIANGLE PARK, NC--(eMediaWorld - December 9, 2008) - In the recent past, drug companies facing patent expirations and dwindling pipelines could find a quick fix for their problems by picking up new technologies and drug candidates via licensing opportunities that held a much smaller price tag than M&A. Now, however, the economic downturn threatens to limit pharmaceutical companies' access to drug development innovations, as many small pharmas and biotechs are being forced to close their doors.

Oncology Drug Iressa Better Than Chemotherapy in Some Patients, According to New Report From Cutting Edge Information

Tue, 09 Dec 2008 08:16:00 EST

RESEARCH TRIANGLE PARK, NC--(eMediaWorld - December 9, 2008) - Iressa's sales are poised to increase on positive clinical results suggesting that AstraZeneca's targeted lung cancer therapy performs better than standard chemotherapy in many patients, according to a new report, "Oncology Market Forecast to 2013" (http://www.cuttingedgeinfo.com/oncology/TA220_ Download.asp), published by pharmaceutical business intelligence leader Cutting Edge Information.

PHT Corporation Partners With CMARC to Offer the Disabled Independence Through Employment

Tue, 09 Dec 2008 08:00:00 EST

Leading Global Supplier of eDiaries for Pharmaceutical Trials Supports Mission of Local Provider of Programs and Services for Disabled

Leading Clinical Proteomics Researchers Choose Ludesi Basic and the Ludesi REDFIN Software for Its 2D Gel Image Analysis

Mon, 08 Dec 2008 08:37:00 EST

New "Ludesi Basic" Offering for 2D Gel Image Analysis Chosen by Clinical Proteomics Researchers at Universidade de Santiago de Compstela

REGiMMUNE Receives $12 Million in Grants to Develop Transplant and Allergy Drugs

Mon, 08 Dec 2008 08:00:00 EST

MOUNTAIN VIEW, CA and TOKYO--(eMediaWorld - December 8, 2008) - REGiMMUNE Corporation, a privately held biopharmaceutical company focused on developing technologies and products for immune disorders, today announced that it has received two separate grants totaling more than $12 million from the Japan Science and Technology Agency (JST) and from National Institute of Biomedical Innovation (NIBIO). Under terms outlined in the five-year grant from JST, REGiMMUNE will develop its reVax drug for cedar allergy; and the three-year grant from NIBIO will fund the development of its ToleroVax drug (RGI-2001), a new immunosuppressant for Graft-versus-Host Disease (GvHD) associated with stem cell transplantation.

Cytokinetics Announces Clinical Trial Data Regarding SB-743921 Presented at the 2008 Annual Meeting of American Society of Hematology

Mon, 08 Dec 2008 07:30:00 EST

SOUTH SAN FRANCISCO, CA--(eMediaWorld - December 8, 2008) - Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that an abstract summarizing interim Phase I data from a clinical trial evaluating SB-743921 in patients with lymphoma was presented as a poster at the 2008 Annual Meeting of the American Society of Hematology (ASH) held on December 6-9, 2008 at the Moscone Center in San Francisco, California. SB-743921 is a novel, small molecule inhibitor of kinesin spindle protein (KSP), a mitotic kinesin essential for proper cell division, being developed by Cytokinetics in collaboration with GlaxoSmithKline.

DOR BioPharma Announces FDA Clearance of IND for DOR201 in Radiation Enteritis

Mon, 08 Dec 2008 07:00:00 EST

EWING, NJ--(eMediaWorld - December 8, 2008) - DOR BioPharma, Inc. (OTCBB: DORB) ("DOR" or the "Company"), a late-stage biopharmaceutical company developing products to treat the life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines against certain bioterrorism agents, announced today that the U.S. Food and Drug Administration (FDA) has completed its review and cleared the Investigational New Drug (IND) application for DOR201, a time-release formulation of oral beclomethasone dipropionate (oral BDP), for the prevention of acute radiation enteritis. DOR is, therefore, cleared to initiate a Phase 1/2 clinical trial in acute radiation enteritis.

Callidus Software Joins Salesforce.com's Force.com Checkout Partner Program

Mon, 08 Dec 2008 07:00:00 EST

SPM Leader One of 14 Companies Exhibiting at Cloudforce Event in New York City on December 8

Cypress Bioscience, Inc. to Present at RBC Capital Markets Healthcare Conference

Mon, 08 Dec 2008 06:30:00 EST

SAN DIEGO, CA--(eMediaWorld - December 8, 2008) - Cypress Bioscience, Inc. (NASDAQ: CYPB) today announced that Sabrina Martucci Johnson, its Chief Operating Officer and Chief Financial Officer, will participate in two panel discussions at the RBC Capital Markets Healthcare Conference on December 10, 2008. The RBC conference is being held at the Westin Times Square in New York, NY. The first panel presentation in which Ms. Johnson will participate, titled 'Reinventing the CNS Therapeutics Armamentarium,' is scheduled for Wednesday, December 10th at 8:00 a.m. Eastern Time. The audio broadcast of this panel presentation can be accessed at http://www.wsw.com/webcast/rbc95/panel1/.

Yvette Roubideaux Honored With American Diabetes Association's Distinguished Service Achievement Award

Fri, 05 Dec 2008 09:51:00 EST

Yvette Roubideaux, MD, MPH, Presented With Addison B. Scoville Award for Outstanding Volunteer Service

Nicole Johnson, Former Miss America, Honored With American Diabetes Association's Distinguished Service Achievement Award

Fri, 05 Dec 2008 09:49:00 EST

Nicole Johnson Presented With Charles H. Best Medal for Distinguished Service in the Cause of Diabetes

Thomas R. Frieden, MD, MPH, Honored With American Diabetes Association's Distinguished Service Achievement Award

Fri, 05 Dec 2008 09:48:00 EST

Thomas R. Frieden, MD, MPH, Presented With C. Everett Koop Medal for Health Promotion and Awareness

Eden Bioscience Announces Board of Directors' Approval of Plan of Dissolution and Liquidation

Fri, 05 Dec 2008 09:00:00 EST

WOODINVILLE, WA--(eMediaWorld - December 5, 2008) - Eden Bioscience Corporation (NASDAQ: EDEN) announced today that its Board of Directors determined, in its best business judgment after consideration of available strategic options, that it is in the best interests of the Company and its shareholders to liquidate the Company's assets and to dissolve the Company. The Company's Board of Directors approved a plan of dissolution and liquidation of the Company (the "Plan"), subject to shareholder approval. The Company intends to hold a special meeting of shareholders to seek approval of the Plan and will file related proxy materials with the Securities and Exchange Commission in the near future.

Norwegian Research Council Names Bionor Immuno "Most Innovative Company of the Year"

Fri, 05 Dec 2008 08:00:00 EST

Researchers Hope Bionor Immuno's Immune Modulating Investigational Treatment Gives HIV Patients a Safe Break From Anti-Retroviral Therapy

PDL BioPharma Resets Record Date for Spin-Off of Biotechnology Operations to December 5

Fri, 05 Dec 2008 08:00:00 EST

Company Continues to Expect Spin-Off Completion on December 18

Functional Technologies Licenses Novel Hydrogen Sulfide Reducing Yeast Technology From University of California

Fri, 05 Dec 2008 07:30:00 EST

VANCOUVER, BRITISH COLUMBIA--(eMediaWorld - Dec. 5, 2008) - Functional Technologies Corp. (TSX VENTURE:FEB) is pleased to announce the exclusive licensing of proprietary hydrogen sulfide (H2S) reducing yeast technology from the University of California at Davis (UC Davis). H2S is a colorless volatile gas which produces a distinctive unpleasant noxious odor in wine, beer, and other fermented beverages. H2S is one of the most common occurring sensory defects, and a widespread problem, in wine production.

Cytokinetics Announces Preclinical and Clinical Trial Data Regarding Ispinesib to Be Presented at the 31st Annual San Antonio Breast Cancer Symposium

Fri, 05 Dec 2008 07:30:00 EST

SOUTH SAN FRANCISCO, CA--(eMediaWorld - December 5, 2008) - Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that two abstracts, one summarizing interim clinical trial data evaluating ispinesib and another regarding preclinical data for ispinesib, are scheduled to be presented as poster presentations at the 31st Annual San Antonio Breast Cancer Symposium (SABCS) to be held December 10-14, 2008 at the Henry B. Gonzalez Convention Center, San Antonio, Texas. Ispinesib is a novel, small molecule inhibitor of kinesin spindle protein (KSP), a mitotic kinesin essential for proper cell division, being developed by Cytokinetics under a collaboration with GlaxoSmithKline.

Ambrilia Biopharma conclut un accord exclusif d'option de licence avec ZBx Corporation lui conférant les droits mondiaux sur sa technologie PSP94 pour diagnostiquer le cancer de la prostate

Thu, 04 Dec 2008 09:20:00 EST

MONTREAL, QUEBEC--(eMediaWorld - 4 déc. 2008) - Ambrilia Biopharma inc. (TSX:AMB) annonce aujourd'hui qu'elle a signé un accord exclusif d'option de licence avec ZBx Corporation accordant à cette dernière des droits pour développer, fabriquer et commercialiser la technologie PSP94 d'Ambrilia qui sera amalgamée aux tests de diagnostic ZAP(MC) Rapid Test Systems and Assays de ZBx. Selon les termes de l'entente, ZBx dispose, à titre exclusif, d'une période de neuf mois pour évaluer s'il est possible d'incorporer la technologie PSP94 d'Ambrilia dépistant le cancer de la prostate dans le système de test diagnostic ZAP(MC) Rapid Test Systems and Assays de ZBx. A tout moment pendant cette période, ZBx pourra exercer son option d'exploitation exclusive de la technologie PSP94. Dès lors, Ambrilia encaisserait des paiements d'étape totalisant jusqu'à 3,62 millions $ US à l'atteinte de jalons de développement et de commercialisation. De plus, Ambrilia toucherait des redevances sur les ventes ai

Ambrilia Biopharma and ZBx Corporation Enter Into an Exclusive License Option Agreement for the Worldwide Rights to Ambrilia's PSP94 Technology for Prostate Cancer Diagnosis

Thu, 04 Dec 2008 09:20:00 EST

MONTREAL, QUEBEC--(eMediaWorld - Dec. 4, 2008) - Ambrilia Biopharma Inc. (TSX:AMB) announced today that it has entered into an exclusive license option agreement with ZBx Corporation granting ZBx the worldwide rights to develop, manufacture and commercialize Ambrilia's PSP94 technology in ZBx's Zap(TM) Rapid Test Systems and Assays. Under the terms of the agreement ZBx is entitled to a 9-month exclusive evaluation period to determine the feasibility of incorporating Ambrilia's PSP94 technology for prostate cancer into ZBx's Zap(TM) Rapid Test Systems and Assays. At any time during this evaluation period ZBx is entitled to exercise its option to an exclusive license upon which Ambrilia would be eligible to receive up to a total of $US3.62 million with the achievement of all development and commercialization milestone payments. In addition, Ambrilia would be entitled to royalties on sales as well as a percentage share from any sublicenses. ZBx will cover all costs associated with the

Broncus Technologies Secures $38 Million in Funding Round Led by Ares Life Sciences

Thu, 04 Dec 2008 09:00:00 EST

MOUNTAIN VIEW, CA--(eMediaWorld - December 4, 2008) - Broncus Technologies, Inc., a medical device company developing products for emphysema and other lung diseases, announced today that it has closed a $38 million round of Series G funding, led by a $25 million investment from Ares Life Sciences AG, a Swiss-based private equity fund. Almost all existing investors are participating in this round, including Abingworth, Bio*One/Singapore, Charter Ventures, HBM BioVentures, JAIC America, Menlo Ventures, Pac-Link Ventures, Saints Capital and Sightline Ventures. Dr. Beat Merz from Ares Life Sciences will join Broncus' Board.

University of Pennsylvania Medication Safety Monitoring Program Places Additional Order for InforMedix's Med-eXpert System and Med-eMonitor Patient Appliances

Thu, 04 Dec 2008 08:52:00 EST

268 Patients to Be Recruited Into Anticoagulation Health Safety-Monitoring Program

National Kidney Registry Announces Howard Gebel, PhD and Steven Katznelson, MD Have Joined Medical Board

Thu, 04 Dec 2008 08:43:00 EST

NEW YORK, NY--(eMediaWorld - December 4, 2008) - The National Kidney Registry, a non-profit organization dedicated to improving the lives of those facing kidney failure, is pleased to announce the addition of Howard Gebel, PhD and Steven Katznelson, MD to its Medical Board. Dr. Gebel is Professor of Pathology and co-director of the Histocompatibility and Molecular Immunogenetics (HLA) Laboratory at Emory University Hospital. Additionally, Dr. Gebel works with a consulting group that manages several other HLA laboratories across the United States. Dr. Gebel is a leading expert in the immunobiology of transplantation with a focus on HLA antibodies and their impact on graft rejection in kidney transplant recipients.

Cutting Edge Information Anticipates the Price of Drugs Will Continue to Rise in 2009

Thu, 04 Dec 2008 08:14:00 EST

RESEARCH TRIANGLE PARK, NC--(eMediaWorld - December 4, 2008) - Pharmaceutical prices rose an average of 31% per year between 2003 and 2007, far outpacing inflation. With this week's announcement from the National Bureau of Economic Research that the US economy has been in a recession since December of 2007, it may come as a shock that, according to a recent report by pharmaceutical business intelligence firm Cutting Edge Information, pharmaceutical prices will continue to rise in 2009. The public criticism regarding drug prices caused Barack Obama and John McCain to criticize the drug industry's prices during their 2008 presidential campaigns. But Cutting Edge Information's report, "Outcomes-Based Pharmaceutical Pricing: Meeting Stakeholder Needs" (http://www.PharmaPricingStrategy.com) outlines the reasons for consistent increases in the costs of drug therapies.

Seegene Receives Approval From Health Canada for Its Respiratory Virus Multi-Pathogen Detection Tests

Wed, 03 Dec 2008 09:00:00 EST

Seeplex(R) RV5 and RV12 Give Canadian Caregivers an Effective Way to Test for a Broad Range of Respiratory Viruses and Pathogens in One Single Test

Cutting Edge Information's Latest Research Examines Pharmaceutical Marketing Spending Trends in the US

Wed, 03 Dec 2008 08:17:00 EST

RESEARCH TRIANGLE PARK, NC--(eMediaWorld - December 3, 2008) - Pharmaceutical business intelligence leader, Cutting Edge Information, announces the launch of a new report, "Driving Successful Pharma Brands: Case Studies of Real Product Launches" (http://www.USPharmaLaunch.com). "Driving Successful Pharma Brands" examines marketing budgets and spending patterns for 13 drugs as they move through product development to US market launch. The brands examined represent a variety of therapeutic areas and drug classes. Compiled from primary research sources -- interviews and surveys conducted with product directors, strategic marketing directors, senior marketing directors, and senior product managers -- the report enables drug companies to benchmark their brands' commercialization resources and identify unique commercialization strategies that can be applied to their drugs' marketing plans.

AVI BioPharma Files IND for Clinical Trial of Marburg Virus Treatment

Wed, 03 Dec 2008 08:05:00 EST

Preclinical Results With AVI-6003 Demonstrate Uniform Survival in Non-Human Primates Following Lethal Virus Challenge

MDRNA Reports UNA-Modified siRNAs Effectively Silence Gene Targets in Animal Models

Wed, 03 Dec 2008 08:00:00 EST

Proprietary DiLA2 Platform Continues to Demonstrate Safe and Effective In Vivo Delivery in Repeat Dose Studies

AVI BioPharma Files IND for Clinical Trial of Ebola Virus Treatment

Wed, 03 Dec 2008 08:00:00 EST

Preclinical Results With AVI-6002 Demonstrate Excellent Survival in the Face of Lethal Virus Challenge

Offer Update

Wed, 03 Dec 2008 06:54:00 EST

CHESHIRE, UK--(eMediaWorld - December 3, 2008) - NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO THE SAME WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION London, 3 December 2008 PROTHERICS PLC ("PROTHERICS") Offer Update: Court confirmation of Reduction of Capital Further to the announcement dated 1 December 2008, Protherics (LSE: PTI) and BTG plc ("BTG") (LSE: BCG) are pleased to announce that the High Court of Justice in England and Wales has today made an order confirming the reduction of Protherics' share capital in connection with the Scheme of Arrangement by which BTG's Acquisition of Protherics is being implemented. This follows the Court's sanction of the Scheme at a hearing held on 1 December 2008. The Scheme will become effective upon the Court Orde

Zecotek Announces the MAPD-3N Solid-State Photo Detector

Wed, 03 Dec 2008 03:00:00 EST

VANCOUVER, BRITISH COLUMBIA--(eMediaWorld - Dec. 3, 2008) - Zecotek Photonics Inc. (TSX VENTURE:ZMS)(FRANKFURT:W1I) today announced that it has initiated delivery of its most advanced Micro-pixel Avalanche Photo Diodes (MAPD) solid-state photo detectors to research centers and key customers in both medical imaging and high-energy physics for immediate use. The proprietary MAPD-3N is the production based design upgrade of the previously announced MAPD. It also offers significant performance advantages over competing photomultiplier tubes (PMT) and the device is more compact and cheaper to manufacture.

Patient Enrolment Completed in Phase II Clinical Trial Evaluating Allon's AL-108 in Schizophrenia-Related Cognitive Impairment

Tue, 02 Dec 2008 09:00:00 EST

VANCOUVER, BRITISH COLUMBIA--(eMediaWorld - Dec. 2, 2008) - Allon Therapeutics Inc. (TSX:NPC) announced today that patient enrolment is complete in a Phase II clinical trial evaluating the safety and efficacy of the Company's proprietary drug candidate AL-108 in patients with schizophrenia-related cognitive impairment. The trial is being managed and funded largely by TURNS (Treatment Units for Research on Neurocognition and Schizophrenia), with support from the U.S. National Institute of Mental Health. Top-line results are expected to be released in 2009.

Caroline Loewy Joins Corcept as Chief Financial Officer

Tue, 02 Dec 2008 09:00:00 EST

MENLO PARK, CA--(eMediaWorld - December 2, 2008) - Corcept Therapeutics (NASDAQ: CORT) today announced the appointment of Caroline M. Loewy to the position of Chief Financial Officer. She will oversee Corcept's financial operations, business development activities, investor relations, and along with other members of the management team, corporate strategy. "We are pleased to have a person with Caroline's financial and biopharmaceutical industry expertise join us at Corcept," said Joseph K. Belanoff, M.D., Chief Executive Officer of Corcept Therapeutics. "Caroline's broad experience will be valuable to Corcept during this significant period in our Company's evolution, as we move CORLUX toward the market with our two ongoing Phase III programs, and advance our second generation selective GRII antagonists into clinical development."

Adeona Pharmaceuticals and National Neurovision Research Institute (NNRI) Collaborate to Test Flupirtine for Retinitis Pigmentosa

Tue, 02 Dec 2008 08:30:00 EST

NNRI to Fully Fund Research for Retinitis Pigmentosa

GSK and Theravance Announce Positive Phase 2b Results for LABA, '444 in the Horizon Asthma Development Programme

Tue, 02 Dec 2008 08:00:00 EST

Initial results demonstrate potential of '444 in the treatment of patients with moderate to severe asthma

Targeted Genetics Realigns Product Development Priorities and Implements Cost Reduction Measures

Tue, 02 Dec 2008 07:30:00 EST

Company Focuses on Clinical Development Path for LCA, HD and ALS; Cuts Costs by Personnel Reductions and Salary Deferrals and Reductions

SciClone Pharmaceuticals Appoints Gary Titus as Chief Financial Officer

Tue, 02 Dec 2008 06:30:00 EST

FOSTER CITY, CA--(eMediaWorld - December 2, 2008) - SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced the appointment of Gary Titus as Chief Financial Officer and Senior Vice President, Finance, effective December 8, 2008. In this position, Mr. Titus will use his significant biotechnology industry experience to lead finance activities and investor relations for the Company as well as oversee human resources, and legal affairs. Mr. Titus will report to Friedhelm Blobel, Ph.D., President and Chief Executive Officer of SciClone.

Addex Starts Phase IIb ADX10059, Proton Pump Inhibitor Combination Study in GERD Patients

Tue, 02 Dec 2008 01:38:00 EST

GENEVA--(eMediaWorld - December 2, 2008) - Addex Pharmaceuticals (SWISS: ADXN), the allosteric modulation company, started today a Phase IIb trial of ADX10059 as an add-on therapy to proton pump inhibitors (PPIs) for the treatment of gastroesophageal reflux disease (GERD), the cause of heartburn and other symptoms. The standard dose of PPI does not control GERD adequately in about 40% of patients. ADX10059 is a first-in-class reflux inhibitor that works by selectively inhibiting the metabotropic glutamate receptor 5 (mGluR5) through negative allosteric modulation. This approach may lead to a new class of drugs that addresses the causes of GERD rather than the symptoms.

Pacgen Reports Second Quarter Financial Results

Mon, 01 Dec 2008 21:00:00 EST

VANCOUVER, BRITISH COLUMBIA--(eMediaWorld - Dec. 1, 2008) - Pacgen Biopharmaceuticals Corporation ("Pacgen" or the "Company") (TSX VENTURE:PGA) today reported financial results from its second fiscal quarter ended September 30, 2008. Amounts unless specified otherwise, are expressed in Canadian dollars and in accordance with Canadian Generally Accepted Accounting Principles (Canadian GAAP). Financial Results The Company recorded a net loss of $642,454 ($0.02 per common share) for the three months ended September 30, 2008 ("Q2 2009"), compared to a net loss of $1,544,854 ($0.05 per common share) for the three months ended September 30, 2007 ("Q2 2008"). On a year-to-date basis, the Company recorded a net loss of $1,949,955 ($0.06 per common share), compared to a net loss of $3,339,510 ($0.11 per common share) for the same period in the preceding fiscal year. The decrease in net loss in each of the periods in Q2 2009 and on a year-to-date basis, as compared to the same periods in th

Theravance Announces New Employment Inducement Awards

Mon, 01 Dec 2008 18:30:00 EST

SOUTH SAN FRANCISCO, CA--(eMediaWorld - December 1, 2008) - Theravance, Inc. (NASDAQ: THRX) today reported that equity awards were made to five new employees. Pursuant to Nasdaq Marketplace Rule 4350(i)(1)(A)(iv), the equity awards were granted under the Theravance, Inc. 2008 New Employee Equity Incentive Plan, which the Board of Directors of Theravance adopted to facilitate the granting of equity awards to new employees. In accordance with Nasdaq rules, these grants were made under an equity incentive plan without stockholder approval. Nasdaq rules require a public announcement of equity awards to be made under this type of plan. Five employees were granted equity awards to acquire an aggregate of 171,376 shares of the Company's common stock, of which 166,000 are stock options and 5,376 are restricted stock unit awards. These equity awards vest over approximately four years and the options expire in 10 years assum

Cytokinetics Announces Clinical Trial Data Regarding SB-743921 to Be Presented at the 2008 American Society of Hematology Annual Meeting and Exposition

Mon, 01 Dec 2008 16:00:00 EST

SOUTH SAN FRANCISCO, CA--(eMediaWorld - December 1, 2008) - Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that an abstract summarizing interim clinical trial data evaluating SB-743921 is scheduled to be presented as a poster presentation at the 2008 American Society of Hematology (ASH) Annual Meeting and Exposition to be held December 6-9, 2008 at the Moscone Center in San Francisco, California. SB-743921 is a novel, small molecule inhibitor of kinesin spindle protein (KSP), a mitotic kinesin essential for proper cell division, being developed by Cytokinetics under a collaboration with GlaxoSmithKline.

MD&DI Wins National Gold Azbee Award From ASBPE for 'Neurotechnology Article'

Mon, 01 Dec 2008 14:05:00 EST

LOS ANGELES, CA--(eMediaWorld - December 1, 2008) - Medical Device & Diagnostic Industry (MD&DI), a Canon Communications publication, and Sherrie Conroy, Editor-in-Chief, were recently honored with a prestigious National Gold Azbee award for Best Feature Article in 2007 by the American Society of Business Publication Editors (A.S.B.P.E). The winning article, "Neurotechnology Offers Relief and Recovery," written by Conroy, was published in the July 2007 issue of MD&DI.

Novogen's NV-128, a Novel mTOR Inhibitor, Shows Potential Activity Against Cancer Stem Cells

Mon, 01 Dec 2008 08:10:00 EST

SYDNEY, AUSTRALIA and NEW CANAAN, CT--(eMediaWorld - December 1, 2008) - Pharmaceutical company Novogen Limited (NASDAQ: NVGN) (ASX: NRT) today announced that work performed in collaboration with a Yale University research team led by Associate Professor Gil Mor, MD, PhD, has revealed its novel mTOR inhibitor NV-128 has the potential to act against cancer stem cells in addition to rapidly proliferating cells in established solid tumors.

Marshall Edwards, Inc. Files IND Application for Triphendiol

Mon, 01 Dec 2008 08:10:00 EST

NEW CANAAN, CT--(eMediaWorld - December 1, 2008) - Marshall Edwards, Inc. (NASDAQ: MSHL) today announced that it has filed an application with the United States Food and Drug Administration for an Investigative New Drug (IND) approval to undertake clinical studies with triphendiol as a chemosensitizing agent in combination with gemcitabine. The IND application is to enable a Phase Ib study of triphendiol in combination with gemcitabine in patients with unresectable, locally advanced or metastatic pancreatic and bile duct cancers.

Auxilium Pharmaceuticals, Inc. Announces Distribution and License Agreement for Testim(R) in Europe With Ferring Pharmaceuticals

Mon, 01 Dec 2008 07:00:00 EST

MALVERN, PA and SAINT-PREX, SWITZERLAND--(eMediaWorld - December 1, 2008) - Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) and Ferring International S.A. today announced an exclusive agreement between them for the European distribution and license rights to Testim®, a proprietary, topical 1% testosterone once-a-day gel indicated for the treatment of hypogonadism. "We are very pleased to have Ferring as our partner, given the strength of their European specialty urology and endocrinology franchises, their existing commercial infrastructure across Europe, and the successful track record they have established in commercializing differentiated products in the European Union," said Armando Anido, Chief Executive Officer and President of Auxilium. "This agreement enables us to bring our innovative testosterone replacement product to patients in all of the 15 countries where Testim has been approved and potentially in

DOR BioPharma Receives $1.5 Million From Sigma-Tau Pharmaceuticals for Exclusive Right to Negotiate orBec(R) Strategic Alliance

Mon, 01 Dec 2008 07:00:00 EST

EWING, NJ--(eMediaWorld - December 1, 2008) - DOR BioPharma, Inc. (OTCBB: DORB) ("DOR" or the "Company") announced today that it has received $1.5 million under a letter of intent with Sigma-Tau Pharmaceuticals, Inc. ("Sigma-Tau"), which grants Sigma-Tau an exclusive right to negotiate terms and conditions for a possible business transaction or strategic alliance regarding orBec® (oral beclomethasone dipropionate or oral BDP) and potentially other DOR pipeline compounds until March 1, 2009.

AngioChem to Present at the 20th Annual Piper Jaffray Health Care Conference

Mon, 01 Dec 2008 07:00:00 EST

MONTREAL, CANADA--(eMediaWorld - Dec. 1, 2008) - AngioChem will present at the upcoming 20th Annual Piper Jaffray Heathcare Conference being held in New York on December 2-3, 2008. The presentation by Dr. Jean-Paul Castaigne MD, MBA, President and Chief Executive Officer, will be on Tuesday, December 2nd at 4:10 pm. Dr. Jean Paul Castaigne will provide a corporate overview and an update on the two on-going internal programs with anti-cancer agents and peptides as well as on the external research collaborations on siRNA and MAbs with a leader in the field.

Protherics PLC announces Offer Update

Mon, 01 Dec 2008 06:36:00 EST

Cheshire, UK--(eMediaWorld - December 1, 2008) - NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO THE SAME WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION London, 1 December 2008 PROTHERICS PLC ("PROTHERICS") Offer Update: Court sanction of Scheme of Arrangement Protherics (LSE: PTI) and BTG plc ("BTG") (LSE: BGC) are pleased to announce that the High Court of Justice in England and Wales has today made an order sanctioning the Scheme of Arrangement by which BTG's Acquisition of Protherics is being implemented. In order for the Scheme to become effective in accordance with its terms, the Court will now need to confirm the associated Reduction of Capital at the Reduction Court Hearing. This hearing will take place on 3 December 2008. Following the confirmation

ImmuneRegen(R) Appoints Wound Healing and Tissue Regeneration Expert Spencer A. Brown, Ph.D. to Advisory Board

Mon, 01 Dec 2008 06:30:00 EST

Company Gains Further Scientific and Biotech Business Expertise to Accelerate Development of, and the Opportunity for Clinical Trials for, New Wound Care Drug

PharmEng Reports Reduced Cash Burn, Financing Update, Strategic Update, Board Member Additions, and Third Quarter Earnings for 2008

Sun, 30 Nov 2008 23:40:00 EST

TORONTO, ONTARIO--(eMediaWorld - Nov. 30, 2008) - PharmEng International Inc. (TSX VENTURE:PII), a full-service consulting and contract manufacturing company, today reported its results for the period ended September 30, 2008. The Company also announced Board changes and provided an update on the strategic plan involving the integration of the newly commissioned Sydney facility. Readers are encouraged to review the Company's complete Interim Consolidated Financial Statements and accompanying Management's Discussion & Analysis which are available under the "investors" section of its website at www.pharmeng.com and on SEDAR at www.sedar.com.

Cryobanks International and Becoming Mom Pregnancy Spa & Ultrasound Imaging Center Team Up to Educate Moms About Umbilical Cord Blood

Sun, 30 Nov 2008 01:00:00 EST

ALTAMONTE SPRINGS, FL--(eMediaWorld - November 30, 2008) - Cryobanks International Inc., a leader in the collection, processing, and banking of umbilical cord blood, is pleased to announce its new partnership with Becoming Mom Pregnancy Spa & Imaging Center located in Mason, OH, a Cincinnati, OH suburb. Through this partnership, Becoming Mom will add umbilical cord blood storage and donation to its long list of specialty services all which promote a healthy pregnancy for its clients. Becoming Mom will be taking an active role in educating their members about their cord blood options while in the comfort of the Becoming Mom Spa environment. Through this program, Becoming Mom Members will be able to donate their cord blood free of cost. Or if they feel private storage is the better option, their Becoming Mom Spa Membership will earn them a discount on Cryobanks International's initial processing and storage fee.

Med BioGene Reports Financial Results for the Third Quarter 2008

Fri, 28 Nov 2008 21:56:00 EST

VANCOUVER, BRITISH COLUMBIA--(eMediaWorld - Nov. 28, 2008) - Med BioGene Inc. (TSX VENTURE:MBI) today reported its financial results for the third quarter of 2008. Erinn Broshko, MBI's Chief Executive Officer stated: "This is an important time for the company as we prepare for the U.S. launch of LungExpress Dx(TM) in mid 2009. LungExpress Dx(TM), our lead product under development, is a gene expression-based test for early stage non-small-cell lung cancer that provides valuable information regarding each patient's prognosis in order to more effectively guide treatment and improve the selection of patients for chemotherapy following surgical removal of their cancerous tumour. Over the last quarter, we broadened our commercialization team and continued to execute upon our strategy for the successful introduction of LungExpress Dx(TM). Furthermore, we completed a $1.8 million financing in challenging global financial markets to facilitate the establishment of our commercial operations."

Great Lakes Biogas Technolgies Inc. Announces New Company Transfer Agency

Fri, 28 Nov 2008 10:56:00 EST

MARIETTA, GA--(eMediaWorld - November 28, 2008) - Great Lakes Biogas Technologies Inc. (PINKSHEETS: GLBS) (FRANKFURT: CS4) has appointed Knightsbridge Assurance Inc. as the company's new transfer of record. Any correspondence or business sent to the old transfer will automatically be forwarded to Knightsbridge Assurance for processing. GLBS issued and outstanding shares to date are 20,849,887.

Acceleware Corp. Announces Third Quarter Results

Fri, 28 Nov 2008 07:00:00 EST

CALGARY, ALBERTA--(eMediaWorld - Nov. 28, 2008) - Acceleware Corp. (the "Corporation" or "Acceleware") (TSX VENTURE:AXE) reported today its financial results for the period ended September 30, 2008. /T/ Third Quarter 2008 Financial Highlights 3 months ended 3 months ended 9 months ended 9 months ended Sep 30, 2008 Sep 30, 2007 Sep 30, 2008 Sep 30, 2007 Revenue $ 472,620 $ 644,023 $ 2,900,910 $ 1,606,924 Net Loss $ 3,108,208 $ 1,795,667 $ 8,181,266 $ 4,616,323 L

Ceapro annonce une augmentation de ses ventes pour son troisième trimestre et la période de neuf mois de 2008

Thu, 27 Nov 2008 09:25:00 EST

EDMONTON, ALBERTA, CANADA--(eMediaWorld - 27 nov. 2008) - Ceapro Inc. (TSX CROISSANCE:CZO) a annoncé aujourd'hui une augmentation de 47 % de ses ventes pour le troisième trimestre terminé le 30 septembre 2008. Le chiffre d'affaires a atteint 871 000 $ comparativement à 591 000 $ pour la même période l'année dernière. Ces chiffres ont été réalisés en dépit d'un taux de change plus faible du dollar américain lors des neuf premiers mois de 2008 et d'une interruption de l'approvisionnement des matières premières suite à une inondation dans le Midwest des Etats-Unis pendant les mois de juillet et d'août. Dans l'ensemble, il existe une demande croissante pour les ingrédients biologiques et naturels actifs de Ceapro, et la Société a pris plusieurs mesures afin d'augmenter les marges brutes et de répondre à la demande croissante prévue pour 2009.

Ceapro Reports Increased Sales in Third Quarter and Nine-Month Period of 2008

Thu, 27 Nov 2008 07:30:00 EST

EDMONTON, ALBERTA, CANADA--(eMediaWorld - Nov. 27, 2008) - Ceapro Inc. (TSX VENTURE:CZO) today reported 47% increase in sales for the third quarter ended September 30, 2008. Revenues reached $871,000 compared with $591,000 in the same period last year. This was achieved despite a lower US dollar exchange rate for the first nine months of 2008 and an interruption in the supply of key raw material due to flooding in the Midwest U.S. during July and August. Globally, there is a growing demand for Ceapro's natural and organic active ingredients and the Company has taken several actions to increase gross margins and to be in a position to respond to an expected overall increased demand in 2009.

Zealand Pharma and Helsinn Healthcare Sign a Partnering Agreement for ZP1846, a Novel GLP-2 Agonist

Thu, 27 Nov 2008 05:16:00 EST

COPENHAGEN, DENMARK--(eMediaWorld - November 27, 2008) - Summary: Zealand Pharma A/S and Helsinn Healthcare SA today announced that it has signed a partnering agreement, for the development and worldwide commercialization of ZP1846, a GLP-2 (glucagon-like peptide-2) receptor agonist which provides a novel way to treat chemotherapy-induced diarrhea (CID), a debilitating condition affecting patients undergoing cancer treatment with a range of chemotherapies. Deal terms Under the terms of the agreement, Helsinn Healthcare will receive a worldwide exclusive license to ZP1846 and will be responsible for all further development, regulatory approvals, manufacturing, marketing and sales of the compound either on its own or through its sub-licensees. In return Helsinn Healthcare will pay Zealand Pharma development milestones and sales milestones for an undisclosed amount. In addition, Zealand Pharma will receive royalties on future sales and Zealand Pharma has retains the

Présentation de MethylGene lors de conférences aux investisseurs

Wed, 26 Nov 2008 14:00:00 EST

MONTREAL, QUEBEC--(eMediaWorld - 26 nov. 2008) - MethylGene Inc. (TSX:MYG) annonce aujourd'hui que son président et chef de la direction, Donald F. Corcoran, participera prochainement à deux conférences aux investisseurs à New York : l'une commanditée par Piper Jaffray, l'autre par RBC Marchés des Capitaux. M. Corcoran fera une présentation à la 20e conférence annuelle Piper Jaffray du secteur médical le mardi 2 décembre à 11h30 (HE). De plus, M. Corcoran participera le jeudi 11 décembre à 8h00 (HE) à une table ronde intitulée "Se battre contre le cancer" ("Waging A Battle Against Cancer"), lors de la conférence 2008 RBC Marchés des Capitaux du secteur médical.

MorphoSys and Galapagos Enter Alliance to Co-develop Novel Therapeutic Antibodies in Bone and Joint Disease

Wed, 26 Nov 2008 02:01:00 EST

Combination of Proprietary Drug Targets and Unique Technologies to Create Range of New Therapeutic Antibodies

Applied Nanoscience Announces Successful EPA-FIFRA Registration for NanoFense(TM) Formulation

Tue, 25 Nov 2008 09:41:00 EST

CARLSBAD, CA--(eMediaWorld - November 25, 2008) - Applied Nanoscience Inc. (ANI) (PINKSHEETS: APNN), a nanotechnology-based filtration development company, today announced that it received notice of a successful EPA-F.I.F.R.A. registration from its exclusive toll manufacturer of NanoFense, a proprietary antimicrobial nanoparticle formulation developed by ANI to coat or impregnate virtually any air filter media. The completed registration positions Applied Nanoscience to supply their patent-pending silver nanoparticle "coating" to air filtration companies around the world via licensure.

DOR BioPharma's orBec(R) Receives Orphan Drug Designation in Australia for the Treatment of GI GVHD

Tue, 25 Nov 2008 08:14:00 EST

EWING, NJ--(eMediaWorld - November 25, 2008) - DOR BioPharma, Inc. (DOR or the Company) (OTCBB: DORB), a late-stage biopharmaceutical company developing products to treat the life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines against certain bioterrorism agents, announced today that the Therapeutics Goods Administration (TGA) of Australia has designated orBec® as an Orphan Drug for the treatment of patients with gastrointestinal Graft-Versus-Host-Disease (GI GVHD) following allogeneic hematopoietic cell transplantation.

Cutting Edge Information Releases Report Showing a 13% Increase of Medical Affairs Groups With Dedicated Budgets

Tue, 25 Nov 2008 08:14:00 EST

RESEARCH TRIANGLE PARK, NC--(eMediaWorld - November 25, 2008) - Nearly 70% of pharmaceutical and biotech companies now have medical affairs teams with dedicated budgets, according to Cutting Edge Information's 2008 report, "Medical Affairs: Delivering Strategic Value" (www.pharmamedicalaffairs.com). Cutting Edge Information's study finds that the percentage of medical affairs groups with their own budgets now stands at 68%, compared to only 55% in a similar 2005 study.

MDRNA, Inc. to Present at Piper Jaffray Healthcare Conference

Tue, 25 Nov 2008 08:00:00 EST

BOTHELL, WA--(eMediaWorld - November 25, 2008) - MDRNA, Inc. (NASDAQ: MRNA) announced today that J. Michael French, President and CEO, will present at the Piper Jaffray Healthcare Conference on Wednesday, December 3, 2008, at 3:00 p.m. Eastern Time (12:00 p.m. Pacific Time), at the Palace Hotel in New York City. To listen to an audio webcast during or after the presentation, please go to: http://www.mdrnainc.com. A replay of the presentation will be available for 30 days.

Skyepharma-PiperJaffray 2008 HealthCare Conference

Tue, 25 Nov 2008 06:42:00 EST

LONDON--(eMediaWorld - November 25, 2008) - SKYEPHARMA TO PRESENT AT PIPER JAFFRAY 2008 HEALTH CARE CONFERENCE LONDON, UK, 25 November 2008 -- SkyePharma PLC (LSE: SKP) announces today that the Company's Chief Executive Officer, Dr Ken Cunningham, and Chief Financial Officer, Peter Grant, will participate in the Piper Jaffray 2008 Health Care Conference in New York. Dr Cunningham's "fireside chat" will take place at 2.30 pm EST (7.30 pm GMT) on Wednesday 3 December 2008. The webcast may be accessed at http://www.skyepharma.com/investor-relations/presentations.html or http://www.piperjaffray.com/conferences. An archived version of the webcast will be available shortly thereafter. Please note that due to the new format of this year's Piper Jaffr

Study Details Annual Medical Cost Increases for People With Diabetes

Tue, 25 Nov 2008 00:01:00 EST

ALEXANDRIA, VA--(eMediaWorld - November 25, 2008) - People diagnosed with diabetes spend over $4,100 more each year on medical costs than people who don't have diabetes, a gap that increases substantially each year following the initial diagnosis, according to a study published online today in the journal Diabetes Care. In the first study to examine medical cost increases for individuals living with diabetes on a year-by-year basis, researchers at RTI International, an independent, nonprofit research institute based in North Carolina, calculated that a 50-year-old newly diagnosed with diabetes spends $4,174 more on medical care per year than a person the same age who doesn't have diabetes. For the person with diabetes, medical costs go up an additional $158 per year every year thereafter, over and above the amount they would increase due to aging-related increases in medical expenses.

Urodynamix Presents First Data on Use of NIRS and Transurethral Microwave Therapy at the 26th World Congress of Endourology Conference

Mon, 24 Nov 2008 09:00:00 EST

VANCOUVER, BRITISH COLUMBIA--(eMediaWorld - Nov. 24, 2008) - Urodynamix Technologies Ltd. (TSX VENTURE:URO) announced today that a multinational team will present an abstract highlighting the use of Urodynamix's near infrared spectroscopy (NIRS) technology for non-invasive measurement of blood flow changes during minimally invasive treatments for benign prostatic hyperplasia (BPH). The abstract, entitled "Initial report of near infrared spectroscopy (NIRS) for non-invasive measurement of blood volume and flow changes to provide treatment feedback during prostate thermal therapies for BPH" will be presented by Prof. Limin Liao of the China Rehabilitation Research Center, David Robertson of Boston Scientific Corporation, and Dr. Luya Li of Urodynamix Technologies. The published abstract will be posted to Urodynamix's website and will also appear on the World Congress of Endourology website at www.chinamed.com.cn/wce2008. The presentation will take place at the 26th Annual Meeting of th

AVI BioPharma Strengthens Patent Position in Exon Skipping

Mon, 24 Nov 2008 08:05:00 EST

PORTLAND, OR--(eMediaWorld - November 24, 2008) - AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, today announced the signing of an exclusive worldwide license agreement with the University of Western Australia (UWA) to a patent application related to the treatment of Duchenne Muscular Dystrophy (DMD). The patent application, "Antisense Oligonucleotides for Inducing Exon Skipping and Methods of Use Thereof" (U.S. Patent publication number US2008/0200409 A1 and foreign counterparts) claims compositions and methods for treating DMD in humans by skipping exons in the dystrophin gene using antisense oligomers. Among the inventors on the licensed patent application is Stephen D. Wilton, Ph.D., Head of the Molecular Genetic Therapies Group at UWA, a renowned pioneer in the use of exon skipping to treat DMD.

NorDx Uses InforSense to Accelerate Analysis of Clinical, Financial and Laboratory Data

Mon, 24 Nov 2008 08:00:00 EST

InforSense Expands Into Operational Healthcare Analytics Market

Chemaphor Announces Proposed Private Placement

Fri, 21 Nov 2008 09:28:00 EST

OTTAWA, CANADA--(eMediaWorld - Nov. 21, 2008) - Chemaphor Inc. (TSX VENTURE:CFR), a biotechnology research and development company today announced plans to seek financing of approximately $1 million, subject to demand for subscriptions, by way of a non-brokered equity private placement. The definitive terms, total amount and pricing of the private placement will be determined through consultation with Chemaphor's advisors and potential subscribers. Closing of the proposed private placement remains speculative at this point and will be subject to the execution of appropriate agreements with any brokers or finders and definitive subscription agreements with subscribers and the receipt of all necessary regulatory approvals, including the approval of the TSX Venture Exchange.

Cutting Edge Information Publishes Report Forecasting DPP-4 Inhibitor Sales to Increase 450% Through 2013

Fri, 21 Nov 2008 08:02:00 EST

RESEARCH TRIANGLE PARK, NC--(eMediaWorld - November 21, 2008) - A recently published therapeutic area forecasting report from pharmaceutical business intelligence leader Cutting Edge Information finds that DPP-4 inhibitors will quickly become the highest-grossing class within the diabetes market, even outpacing the long-acting insulins. The DPP-4 class entered the market in 2006 when Merck won approval to market Januvia. The class has three distinct advantages setting it apart from competitors: a lowered risk for hypoglycemia, a lowered risk for weight gain, and an oral formulation. Though Januvia remains the only FDA-approved DPP-4 inhibitor, two rivals are racing through development, and both are expected to reach blockbuster status.

MattsonJack Study Reveals Cachexia Emerging as a Lucrative Opportunity for Pharma Companies

Thu, 20 Nov 2008 10:06:00 EST

ST. LOUIS, MO--(eMediaWorld - November 20, 2008) - Cachexia has emerged as a high-profile, high-potential-value supportive care indication in the oncology market and is potentially the most competitive and lucrative indication for the first novel agent approved, according to a physician study conducted by The Mattson Jack Group, Inc. (MattsonJack), a recognized leader in business analytics for the pharmaceutical and healthcare industries. According to MattsonJack's Supportive Care PerspectivesT report series, cancer-induced nausea and vomiting (CINV), anemia, and neutropenia historically have been the high-profile supportive care indications. However, the CINV market has become increasingly competitive due to generic erosion as well as increased efficacy benchmarks set by new branded agents such as Aloxi and the NK1 receptor antagonists, driving development activities to f

Merial Selects Silver Peak Systems for WAN Acceleration

Thu, 20 Nov 2008 09:11:00 EST

NX Appliances Transform Business Processes; Cut IT Costs as Part of a Global Application Centralization Initiative

Aldagen Announces Positive Phase 1/2 Results for Critical Limb Ischemia Stem Cell Therapy ALD-301

Thu, 20 Nov 2008 09:00:00 EST

DURHAM, NC--(eMediaWorld - November 20, 2008) - Aldagen today announced positive results from its multicenter Phase 1/2 clinical trial of ALD-301, a novel stem cell therapy being developed for the treatment of critical limb ischemia. In the 24-week Phase 1/2 trial, ALD-301 was well tolerated. Importantly, the study results also indicated that during the 12-week efficacy assessment period, there were improvements in overall clinical status as well as increased blood flow in the affected limb in the group of patients treated with ALD-301.

Chembio Ships First DPP(R) Tests

Thu, 20 Nov 2008 08:50:00 EST

Milestone Reached With Patented Technology

Cardima Signs Peerless Medical as Distributor for the Midwest Surgical Market

Thu, 20 Nov 2008 08:45:00 EST

FREMONT, CA--(eMediaWorld - November 20, 2008) - Cardima, Inc. (OTCBB: CADM) has engaged St. Louis-based Peerless Medical Inc. as the distributor for the Cardima Surgical Ablation System in the Midwestern United States, including the St. Louis, Kansas City, Wichita, Topeka and Omaha markets. Peerless, which enjoys strong relationships with leading cardiac surgeons in these territories, will market Cardima's Surgical Ablation System and solutions for cardiac patient care beginning immediately.

Cavit Sciences, Inc. Announces Update to Shareholders

Thu, 20 Nov 2008 08:00:00 EST

PATERSON, NJ--(eMediaWorld - November 20, 2008) - Cavit Sciences, Inc. ("Cavit") (OTCBB: CVIT) announced today the following update to its shareholders: To: The Shareholders of Cavit Sciences, Inc. From: Margaret ("Maggie") Smyth, Interim CEO Effective November 14, 2008, I have been elected as Interim CEO of Cavit in order to move our Company forward. Effective November 14, 2008, the corporate headquarters and related facilities of Cavit are located in Paterson, NJ.

Trinity Biotech Announces Appointment of Clint Severson as a Non-Executive Director

Thu, 20 Nov 2008 08:00:00 EST

DUBLIN, IRELAND--(eMediaWorld - November 20, 2008) - Trinity Biotech plc (NASDAQ: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced it has appointed Clint Severson to its Board as a non-executive director. Clint Severson is currently Chairman, President and CEO of Abaxis Inc., a NASDAQ traded diagnostics company based in Union City, California. Since November 2006, Mr. Severson has also served on the Board of Directors of CytoCore, Inc. To date he has accumulated over 30 years experience in the medical diagnostics industry and in 2007 he received the prestigious Entrepreneur of the Year award from Forbes Magazine.

Protherics PLC announces Regulatory Application

Thu, 20 Nov 2008 02:00:00 EST

CHESHIRE, UK--(eMediaWorld - November 20, 2008) - Protherics PLC VoraxazeTM rolling BLA submission initiated with the US FDA London, UK; Brentwood, TN, US; 20 November 2008 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, today announces that it has commenced the submission of a rolling Biologics License Application (BLA) for Voraxaze with the Food and Drug Administration (FDA) in the US. This marketing application is being made for the interventional use of Voraxaze for the rapid and sustained reduction of methotrexate (MTX) in patients who have toxic MTX levels due to impaired renal function. Voraxaze contains an enzyme that breaks down MTX, a commonly used cancer drug. It is an investigational new drug that is available in the US under a Treatment Protocol for patients receiving high dose MTX (? 1g/m2) who are experiencing, or at risk of, MTX toxicity. High dose MTX is used to treat or

Protherics PLC announces Interim Results

Thu, 20 Nov 2008 02:00:00 EST

Cheshire, UK--(eMediaWorld - November 20, 2008) - PROTHERICS ANNOUNCES INTERIM RESULTS FOR SIX MONTHS ENDED 30 SEPTEMBER 2008 Strong revenue growth and significant pipeline development Recommended all share offer from BTG plc London, UK, Brentwood, TN, 20 November 2008 - Protherics PLC ("Protherics" or the "Company"), the biopharmaceutical company focused on critical care and cancer, today announces its unaudited interim results for the six months ended 30 September 2008. Proposed Merger with BTG plc . Recommended all share offer from BTG plc to create one of the UK's leading specialty biopharmaceutical companies: - Protherics shareholders offered 0.291 BTG shares for each Protherics share and on completion will own approximately 40.8% of the enlarged company - Approved by both Protherics and BTG shareholders at respective EGMs - Merger completion expec

Tongli Pharmaceuticals Announces Strong Revenue and Net Income Growth in Second Quarter of Fiscal Year 2009

Wed, 19 Nov 2008 12:17:00 EST

NEW YORK, NY--(eMediaWorld - November 19, 2008) - Tongli Pharmaceuticals (OTCBB: TGLP), a pharmaceutical company specializing in development, manufacture, and commercialization of a wide range of prescription and over the counter ("OTC") pharmaceutical products, today announced financial results for the quarter ended September 30, 2008. Financial Results Revenue in the second quarter of fiscal year 2009 increased 298% year over year to $1,645,540 from $413,034, and revenues in the six months ended September 30, 2008 increased 328% year over year to $3,310,710 from $773,574, reflecting an increase in product demand attributable to increased brand recognition, effective pricing strategy and penetration into previously unaddressed markets.

Symbollon Initiates Sales of IoGen Through Web Site BuyIoGen.com

Wed, 19 Nov 2008 11:54:00 EST

FRAMINGHAM, MA--(eMediaWorld - November 19, 2008) - Symbollon Pharmaceuticals, Inc. (OTCBB: SYMBA) is pleased to announce that it has initiated retail sales of IoGenT, its dietary supplement for women's breast health, through its web site, www.BuyIoGen.com. IoGen is the first dietary supplement formulated to promote breast health for women. IoGen can be purchased in 2 month (60 tablets) and 4 month (120 tablets) quantities.

Sunshine Bio Investments World Launches Funding Initiatives in Multi-Billion Dollar North American Markets Serving Stem Cell Research, Genomics, Proteonomics, Nanotechnologies, Mass Spectrometers, SNPs, PCRs and RFID

Wed, 19 Nov 2008 10:15:00 EST

MIAMI, FL--(eMediaWorld - November 19, 2008) - Sunshine Bio Investments World, a privately held Canadian company (http://www.sunshinebioworld.com), has established U.S. headquarters in Miami and initiated venture funding for a variety of biotech, pharmaceutical and medical device companies active in the multi-billion dollar North American biotech environment. Miami operations are located at 5600 Collins Avenue, Suite 17C, Miami, Florida, 33140. Telephone is 305-433-2121.

Kalorama Finds Demand for Smoking Cessation Drugs Still Strong Despite Chantix' Safety Issues

Wed, 19 Nov 2008 10:06:00 EST

NEW YORK, NY--(eMediaWorld - November 19, 2008) - With approximately 1.4 billion people worldwide addicted to nicotine and more than 5 million resulting deaths each year, there is a major global need for smoking cessations products, as well as education and awareness measures to reduce the number of smokers. A new report from Kalorama Information, "Smoking Cessation: World Markets," finds a 32.6% increase in sales of smoking cessation products from 2006 to 2007, due in large part to the approval of Pfizer's Chantix in late 2006.

PDL BioPharma Announces Record Date for Spin-Off of Biotechnology Operations

Wed, 19 Nov 2008 09:06:00 EST

REDWOOD CITY, CA--(eMediaWorld - November 19, 2008) - PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) announced today that its board of directors has set December 3, 2008 as the record date for the spin-off of PDL's biotechnology operations, which will be accomplished through a pro rata stock dividend to PDL's stockholders of the common stock of Facet Biotech Corporation. Each PDL stockholder of record as of 5:00 p.m. Eastern Time on December 3, 2008 will receive on the distribution date one share of Facet Biotech common stock for every five shares of PDL common stock. The company expects Facet Biotech will trade on Nasdaq under the symbol "FACT" after the spin-off.

Advanced Proteome Therapeutics Corporation Announces Board Resignations and Audit Committee Chairman Appointment

Wed, 19 Nov 2008 09:02:00 EST

VANCOUVER, BRITISH COLUMBIA--(eMediaWorld - Nov. 19, 2008) - Advanced Proteome Therapeutics Corporation (TSX VENTURE:APC) has announced today the resignations of two Board members, Robert Bender and Russell E. Phares, effective October 11. Alexander (Allen) Krantz stated that "the Company was fortunate to have had the services of Robert Bender and Russell Phares in the initial stages of its development. Robert has provided effective counsel and sage advice on diverse matters in support of the Company during its infancy and we are grateful for his enthusiastic commitment to the success of our programs." Mr. Bender indicated that despite his resignation "I remain interested in the development of APT and, should you desire my input, will make whatever efforts I can to be of assistance to you and the Company."

Ambrilia Initiates Plan Aiming to Significantly Reduce its Operations in France

Wed, 19 Nov 2008 09:01:00 EST

ATTENTION BUSINESS/FINANCIAL/HEALTH EDITORS

Ambrilia envisage un projet pouvant conduire à une réduction significative de ses activités en France

Wed, 19 Nov 2008 09:00:00 EST

ATTENTION DIRECTEURS DES RUBRIQUES AFFAIRES/FINANCE/SANTE

CryoPort Collaborates With Advinus Therapeutics

Wed, 19 Nov 2008 08:50:00 EST

LAKE FOREST, CA--(eMediaWorld - November 19, 2008) - CryoPort, Inc. (OTCBB: CYRX) today announced that it is collaborating with Advinus Therapeutics on commercial CryoPort ExpressT shipments to India. The collaboration has involved shipping frozen samples from two sites in the U.S. to Bangalore for analysis. Advinus is one of the leading R&D alliances and pharmaceutical research outsourcing companies in India, part of the Tata Group, one of India's largest and most respected business conglomerates.

Free Symyx Draw 3.1 Download for Academic and Non-Commercial Personal Use

Wed, 19 Nov 2008 08:00:00 EST

Innovative Chemical Structure Drawing Software Replaces ISIS/Draw, Offers Superior Publication-Quality Graphics

Cutting Edge Information Releases Study Showing Drug Companies Tap High-Population Developing Nations for Clinical Trial Subjects

Wed, 19 Nov 2008 07:47:00 EST

RESEARCH TRIANGLE PARK, NC--(eMediaWorld - November 19, 2008) - Clinical trial patient recruitment and retention has the greatest impact on clinical trial costs, according to "Streamlining Clinical Trials" (www.clinicaltrialbenchmarking.com), a new study by pharmaceutical business intelligence leader Cutting Edge Information. Not only does patient recruitment and retention affect direct trial costs, but they also can have a huge bottom-line impact when they delay drug trials and, ultimately, new product launches. As a result, drug companies are increasingly relying on high-population developing nations as a source of new study patients.

Trading in Theravance Common Stock Halted

Wed, 19 Nov 2008 07:05:00 EST

FDA Advisory Committee to Review Telavancin NDA

SciClone Secures $6 Million in Debt Financing From Silicon Valley Bank

Wed, 19 Nov 2008 06:30:00 EST

FOSTER CITY, CA--(eMediaWorld - November 19, 2008) - SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Silicon Valley Bank will provide the company's operating subsidiaries a $6,000,000 debt financing ("the Bank Line"). The Bank Line will be used to provide additional working capital to support SciClone's growth. "This Bank Line provides SciClone with additional financial flexibility as we focus our plans on growing our revenue-generating business," said Friedhelm Blobel, Ph.D., President and Chief Executive Officer of SciClone.

Sanguine Corporation Announces Letter of Intent to Acquire an MRI Imaging Technology Company

Wed, 19 Nov 2008 06:00:00 EST

PASADENA, CA--(eMediaWorld - November 19, 2008) - Sanguine Corporation (OTCBB: SGUI) is pleased to announce that the Company has signed a Letter of Intent, which is subject to a 5 million dollar capitalization agreement, to acquire Rockland Technimed Ltd., a Delaware corporation, whose flagship products are poised to cause a possible shift in MRI imaging with applications in tumor detection, tracking tumor angiogenesis, assess tissue viability in cases of Neurological and Cardiovascular catastrophes such as Heart or Stroke attack, or other tissue injury, and noninvasive real-time tissue stress monitoring to evaluate normal and abnormal oxygen consumption rates.

TimeLogic Achieves the Performance of 471 CPU-Cores for HMM Searches Using Single FPGA Accelerator

Wed, 19 Nov 2008 05:00:00 EST

CARLSBAD, CA--(eMediaWorld - November 19, 2008) - Active Motif's TimeLogic® division announced that their SeqCruncherT PCIe accelerator card enables a single server to search hidden Markov model (HMM) databases with the equivalent performance of 471 Xeon CPU-cores. Search tests were run to compare the performance range, flexibility and scalability of the new SeqCruncher field programmable gate array (FPGA) hardware and improved DeCypherHMM software against the established standard open-source software, HMMER from Dr. Sean Eddy (HHMI). SeqCruncher provided 471x, 863x, and 1151x faster performance per CPU core with 1, 2 and 3 cards when searching an HMM database.

The Visible Body, the First Comprehensive 3D Human Anatomy Visualization and Learning Tool, Now Cross-Platform and Cross-Browser

Tue, 18 Nov 2008 10:00:00 EST

Free, Web-Based Interactive Model Offering Unparalleled Understanding of the Human Body Now Available for Mac OS X, Firefox, and Safari

AspenBio Pharma Reports on FDA 510(k) Clinical Trial Progress for AppyScore, World's First Blood-Based Diagnostic Test for Human Appendicitis

Tue, 18 Nov 2008 09:53:00 EST

Over 700 Patients Now Enrolled in Ongoing 800 Patient Trial

Allon Drugs Receive U.S. Patent for Treatment of Neuropathy

Tue, 18 Nov 2008 09:00:00 EST

VANCOUVER, BRITISH COLUMBIA--(eMediaWorld - Nov. 18, 2008) - Allon Therapeutics Inc. (TSX:NPC) announced today that it has been issued a United States patent covering the use of its neuroprotective drugs as potential treatments for peripheral neuropathy, a group of debilitating and painful conditions suffered by millions of people and resulting from nerve damage for which there is currently no effective treatment available. Among the major causes of neuropathy are diabetes and cancer chemotherapy.

CardioComm Solutions, Inc. and GE Healthcare Sign Long Term Software Agreement

Tue, 18 Nov 2008 09:00:00 EST

VICTORIA, BRITISH COLUMBIA--(eMediaWorld - Nov. 18, 2008) - CardioComm Solutions, Inc. (TSX VENTURE:EKG) ("CardioComm" or the "Company") is pleased to announce that it has executed a renewable four year North American software licensing agreement with General Electric Company through its GE Healthcare business focusing on cardiac arrhythmia management. CardioComm's patented Global ECG Management System (GEMS(TM)) has been selected to be seamlessly integrated within GE's arrhythmia analysis and diagnostic system and will provide a server based solution for both large cardiology practices and in hospital use.

Thallion débute le recrutement pour son essai de Phase II mené auprès de patients atteints d'un mélanome métastatique

Tue, 18 Nov 2008 07:00:00 EST

MONTREAL, QUEBEC--(eMediaWorld - 18 nov. 2008) - Thallion Pharmaceutiques Inc. (TSX:TLN) a annoncé aujourd'hui qu'un premier patient avait été recruté dans le cadre de son essai clinique de Phase II, évaluant TLN-232 comme traitement auprès de patients atteints d'un mélanome métastatique et ayant suivi préalablement une thérapie sans toutefois en bénéficier. "Grâce au lancement réussi de cet essai de Phase II, TLN-232 emboîte maintenant le pas à notre autre médicament-candidat anticancéreux, TLN-4601, nous permettant de mener deux essais cliniques dans le domaine de l'oncologie et de recruter maintenant activement des patients pour ces deux études cliniques" a déclaré M. Lloyd M. Segal, Chef de la direction chez Thallion Pharmaceutiques. "Notre objectif immédiat en matière de développement consiste à reproduire le taux de réponse que nous avons observé lors de l'essai précédemment mené auprès d'un nombre plus restreint de patients atteints d'un mélanome métastatique et à développer u

Thallion Initiates Enrollment in Phase II Metastatic Melanoma Trial

Tue, 18 Nov 2008 07:00:00 EST

MONTREAL, QUEBEC--(eMediaWorld - Nov. 18, 2008) - Thallion Pharmaceuticals Inc. (TSX:TLN) today announced that the first patient has been enrolled in its Phase II trial evaluating TLN-232 as a treatment for metastatic melanoma in patients who have failed one prior therapy. "With the successful initiation of this Phase II trial, TLN-232 now joins our other pipeline candidate, TLN-4601, to give us two Phase II oncology trials actively recruiting patients," said Lloyd M. Segal, Chief Executive Officer of Thallion Pharmaceuticals Inc. "Our immediate development goal is to replicate the significant response rate we achieved in the smaller, prior metastatic melanoma trial and to bring forward an important potential new treatment option for these cancer patients."

Perceptronix to Exhibit at St. Paul's Hospital Annual CME Conference

Mon, 17 Nov 2008 15:51:00 EST

VANCOUVER, BRITISH COLUMBIA--(eMediaWorld - Nov. 17, 2008) - Perceptronix Medical Inc. will be exhibiting at the St. Paul's Hospital Annual Continuing Medical Education Conference from November 18 - 21. Perceptronix will be showcasing LungSign(TM), an innovative early lung cancer test currently available for lung cancer risk assessment, as well as premiering an instructional video demonstrating its use. The company will be exhibiting at booth 127 at the Vancouver Convention & Exhibition Centre. L

ALDA Ready to Ship New T36(R) Disinfectant Cleaner CONCENTRATE

Mon, 17 Nov 2008 10:25:00 EST

VANCOUVER, BRITISH COLUMBIA--(eMediaWorld - Nov. 17, 2008) - ALDA Pharmaceuticals Corp. (TSX VENTURE:APH), ("ALDA") announces that its new "T36(R) Disinfectant Cleaner CONCENTRATE" (DIN 02278820) has been manufactured and delivered and is now ready to be shipped to distributors. T36(R) Disinfectant Cleaner CONCENTRATE is the latest addition to ALDA's infection-control products and complements its T36(R) Disinfectant, T36(R) Hand Sanitizer, T36(R) "Ready to Use" Disinfectant Cleaner, T36(R) Antiseptic Hand Sanitizer and T36(R) Disinfex Disinfectant Spray.

Theravance Announces Posting of Briefing Documents for FDA Anti-Infective Drugs Advisory Committee Meeting on Telavancin

Mon, 17 Nov 2008 09:23:00 EST

SOUTH SAN FRANCISCO, CA--(eMediaWorld - November 17, 2008) - Theravance, Inc. (NASDAQ: THRX) today announced that the U.S. Food and Drug Administration (FDA) has posted on its website briefing documents for the November 19, 2008 Anti-Infective Drugs Advisory Committee (AIDAC) meeting. The AIDAC will be asked to review and discuss Theravance's New Drug Application (NDA) for telavancin, a novel, bactericidal, once-daily injectable investigational antibiotic, for the proposed indication to treat complicated skin and skin structure infections (cSSSI) caused by Gram-positive bacteria, including resistant pathogens such as methicillin-resistant Staphylococcus aureus (MRSA).

Allon Therapeutics Reviews Product Development at BIO-Europe 2008

Mon, 17 Nov 2008 09:00:00 EST

VANCOUVER, BRITISH COLUMBIA--(eMediaWorld - Nov. 17, 2008) - Allon Therapeutics Inc. (TSX:NPC), will review progress of its clinical-stage Alzheimer's disease and preclinical-stage peripheral neuropathy programs November 18 at BIO-Europe 2008 in Mannheim, Germany, the largest European partnering conference for the global biotechnology industry. Gordon McCauley, President and CEO of Allon, will also review the Company's cash management strategy. The Company completed a $20 million equity financing July 15 ensuring its ability to continue progress in all its drug development programs, including providing sufficient funds to undertake and complete a Phase IIb clinical trial in patients with mild-to-moderate Alzheimer's.

KIKA Medical Names Senior Industry Executive Vice President of Professional Services

Mon, 17 Nov 2008 09:00:00 EST

Expert in Project Management Has Extensive Experience Guiding Clients Through Electronic Data Capture (EDC)

Advanced Proteome Therapeutics Makes Major Advance in Technology Development

Mon, 17 Nov 2008 09:00:00 EST

VANCOUVER, BRITISH COLUMBIA--(eMediaWorld - Nov. 17, 2008) - Advanced Proteome Therapeutics Corporation (TSX VENTURE:APC) is pleased to announce that its subsidiary Advanced Proteome Therapeutics Inc. (APT) has achieved a major advance in the development of its core, proprietary technology, kinetic labelling libraries. The Company has produced kinetic labelling libraries in order to screen protein targets for sites along their surfaces to which therapeutic enhancing entities, diagnostic agents and other commercially viable entities can be specifically attached to form protein conjugates. Such conjugates have been constructed to deal with the difficulties of deploying "bare" proteins as therapeutics, which have become a growing and important class of drugs, but have severe limitations. The addition of appropriate appendages (e.g., polyethylene glycol chains) to therapeutic proteins have improved their duration of action and other pharmacokinetic properties, and in several instances ha